Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate, ADS-5102, is being developed for a complication of Parkinson’s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as Ne...
2200 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $728.0K
Senior Vice President of Product Development
Total Annual Compensation: $561.5K
Compensation as of Fiscal Year 2013.
Adamas Pharmaceuticals, Inc. Key Developments
Adamas Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:30 PM
Nov 18 14
Adamas Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Gregory T. Went, Chairman and Chief Executive Officer.
Adamas Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 4 14
Adamas Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $0.215 million against $0.161 million a year ago. Loss from operations was $9.550 million against $2.797 million a year ago. Loss before income taxes was $9.551 million against $3.223 million a year ago. Diluted net loss attributable to common stockholders was $9.557 million or $0.57 per share against $3.439 million or $0.36 per share a year ago.
For the nine months, the company reported revenue of $25.545 million against $30.985 million a year ago. Income from operations was $1.478 million against $21.894 million a year ago. Income before income taxes was $0.667 million against $20.480 million a year ago. Diluted net income attributable to common stockholders was $54,000 against $13,294,000 or $1.19 per share a year ago. Net cash provided by operating activities was $7.240 million against net cash used in operating activities of $9.772 million a year ago. Purchase of property and equipment was $194,000 against $162,000 a year ago. Revenues recognized in both periods were from development milestone payments and development expense reimbursement from Adamas' collaboration with Forest, as well as from government grants and contracts.
Adamas Pharmaceuticals Expands its Phase 3 Program with ADS-5102 for the Treatment of Levodopa
Oct 28 14
Adamas Pharmaceuticals, Inc. announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime. The randomized, double-blind, placebo-controlled study, known as "EASE LID 3," is planned to enroll approximately 70 patients with LID. The 13-week study will include an estimated 35 sites in the U.S and Europe. Participants will receive 340 mg of ADS-5102 or placebo daily. The primary endpoint of EASE LID 3 is a reduction in dyskinesia assessed by changes in the Unified Dyskinesia Rating Scale (UDysRS). EASE LID 3 is one of three ongoing clinical trials for the treatment of LID in individuals with Parkinson's disease. The complete company-sponsored program includes: EASE LID 3, a Phase 3 study (described above), which is estimated to enroll approximately 70 patients. The 13-week multi-center, randomized, double-blind, placebo-controlled study will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. EASE LID, a Phase 3 trial, which is planned to enroll approximately 130 patients. The 26-week multi-center, randomized, double-blind, placebo-controlled trial will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint of EASE LID is a reduction in dyskinesia assessed by changes in UDysRS. EASE LID 2, a Phase 3 open-label safety study of ADS-5102 in Parkinson's disease patients with LID.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|